文献速递冠心病

急性冠脉综合征患者流感疫苗接种策略:VIP-ACS试验

Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial.
PubMed 文献 · Eur Heart J · 2022-01-01

VIP-ACS是一项在巴西25个中心开展的实用型随机对照试验,纳入1801例急性冠脉综合征住院患者,比较出院前双倍剂量四价灭活流感疫苗与出院后30天门诊标准剂量接种两种策略。主要终点为全因死亡、心肌梗死、卒中、不稳定型心绞痛、心衰住院、紧急血运重建和呼吸原因住院的分层复合终点,采用win ratio法分析,随访12个月。结果显示两组主要终点无差异(win ratio 1.02,95%CI 0.79-1.32,P=0.84),双倍剂量住院接种未减少心肺事件。

要点

  • ACS住院患者出院前双倍剂量流感疫苗未优于门诊标准剂量接种。
  • 主要复合终点win ratio 1.02(95%CI 0.79-1.32,P=0.84),两组无差异。
  • 关键次要终点和首次事件分析结果与主要分析一致。

核心结论

  • ACS住院患者出院前双倍剂量流感疫苗接种与门诊标准剂量接种相比,未减少心肺结局。

研究设计与样本

  • 实用型、随机、多中心、活性对照、开放标签试验,结局裁定设盲,比较ACS后两种流感疫苗接种策略。
  • 在巴西25个中心、两个流感季节共纳入1801例参与者,随访12个月。

主要发现

  • 主要分层复合终点win ratio为1.02(95%CI 0.79-1.32,P=0.84),住院双倍剂量组 wins 12.7%,标准剂量组12.3%。
  • 关键次要复合终点(心血管死亡、心肌梗死和卒中)win ratio为0.94(95%CI 0.66-1.33,P=0.72)。
  • 主要终点首次事件分析风险比0.97(95%CI 0.75-1.24,P=0.79)。
  • 不良事件不频繁且两组间无差异。

临床怎么用

  • ACS住院期间出院前双倍剂量流感疫苗接种策略未显示额外获益,不支持以此替代指南推荐的门诊标准剂量接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate whether a strategy of double-dose influenza vaccination during hospitalization for an acute coronary syndrome (ACS) compared with standard-dose outpatient vaccination (as recommended by current guidelines) would further reduce the risk of major cardiopulmonary events. METHODS AND RESULTS: Vaccination against Influenza to Prevent cardiovascular events after Acute Coronary Syndromes (VIP-ACS) was a pragmatic, randomized, multicentre, active-comparator, open-label trial with blinded outcome adjudication comparing two strategies of influenza vaccination following an ACS: double-dose quadrivalent inactivated vaccine before hospital discharge vs. standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization. The primary outcome was a hierarchical composite of all-cause death, myocardial infarction, stroke, unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory causes, analysed by the win ratio method. Patients were followed for 12 months. During two influenza seasons, 1801 participants were included at 25 centres in Brazil. The primary outcome was not different between groups, with 12.7% wins in-hospital double-dose vaccine group and 12.3% wins in the standard-dose vaccine group {win ratio: 1.02 [95% confidence interval (CI): 0.79-1.32], P = 0.84}. Results were consistent for the key secondary outcome, a hierarchical composite of cardiovascular death, myocardial infarction and stroke [win ratio: 0.94 (95% CI: 0.66-1.33), P = 0.72]. Time-to-first event analysis for the primary outcome showed results similar to those of the main analysis [hazard ratio 0.97 (95% CI: 0.75-1.24), P = 0.79]. Adverse events were infrequent and did not differ between groups. CONCLUSION: Among patients hospitalized with an ACS, double-dose influenza vaccination before discharge did not reduce cardiopulmonary outcomes compared with standard-dose vaccination in the outpatient setting. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number: NCT04001504.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Fonseca, Furtado, Zimerman, et al. Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial. Eur Heart J. 2022. PMID: 36030400. doi:10.1093/eurheartj/ehac472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。